OMED OncoMed Pharmaceuticals Inc.

0.83
-0.06  -7%
Previous Close 0.89
Open 0.91
Price To Book 0.62
Market Cap 32070746
Shares 38,630,145
Volume 674,937
Short Ratio
Av. Daily Volume 597,002

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 10, 2017 - primary endpoint not met.
Demcizumab plus Abraxane - YOSEMITE
First-line pancreatic cancer
Announced November 1, 2016 that it has discontinued further enrollment. Phase 2 data released May 8, 2017 - endpoints not met.
Demcizumab plus carboplatin and pemetrexed - DENALI
First-line non-squamous Non-small cell lung cancer (NSCLC)
Phase 2 data released April 17, 2017 - primary endpoint not met.
Tarextumab - PINNACLE trial
Small cell lung cancer
Company announced late January 2016 that they plan to unblind the trial following notice from the DSMB that suggests a low likelihood of a statistically significant benefit in overall survival. Subsequently, in February 2016 an announcement was made to discontine the trial
Tarextumab ALPINE
Pancreatic Cancer
Phase 1b data ESMO October 2018 noted PFS 5.4 months.
Navicixizumab
Ovarian cancer
Data from Phase 1a portion due at SITC November 9, 2018. SD 39%.
Anti-TIGIT (OMP-313M32)
Solid tumors
Phase 1a data due 2019.
GITRL-Fc (OMP-336B11)
Locally Advanced or Metastatic Tumor